A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 27, 2018

Primary Completion Date

August 5, 2018

Study Completion Date

August 5, 2018

Conditions

Healthy Subjects

Interventions

DRUG

ACT-246475

Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475

Trial Locations (3)

Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen

Universitäts-Herzzentrum Freiburg, Freiburg im Breisgau

Universitäts-Herzzentrum Bad Krozingen, Bad Krozingen

All Listed Sponsors

lead

Viatris Innovation GmbH

INDUSTRY

NCT03593278 - A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects | Biotech Hunter | Biotech Hunter